Dinutuximab clinical trials
Also written Ch14.18, Unituxin and Qarziba.
How each study uses dinutuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dinutuximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Mar 2015 · UNITUXIN · BLA 125516 (FDA, Drugs@FDA)
- European Union
- 14 Aug 2015 · Unituxin · EMEA/H/C/002800 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
35 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2005 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 32
National Cancer Institute (NCI) (9) · New Approaches to Neuroblastoma Therapy Consortium (4) · University of Birmingham (2) · United Therapeutics (2) · St. Anna Kinderkrebsforschung (2) · Children's Hospital Los Angeles (1) · Nationwide Children's Hospital (1) · Children's Oncology Group (1)
Often tested with
Tested in the same studies.
Irinotecan (8) · Temozolomide (6) · Isotretinoin (3) · Natural Killer Cell (3) · Sargramostim (3) · Granulocyte-Macrophage Colony-Stimulating Factor (3) · Lenalidomide (2) · Bevacizumab (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 2 in phase 3
Studies that test dinutuximab, phase 3 first.
- Nov 2026High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
- Dec 2026Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaPhase 3 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Dec 2026NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabPhase 1/2 · Nationwide Children's Hospital
- Dec 2026Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsPhase 1 · New Approaches to Neuroblastoma Therapy Consortium
- Mar 2027International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing SarkomaPhase 1 · Prof. Dr. Dr. Birgit Burkhardt
Studies
Open first, then newest update. How each study uses dinutuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 35
- International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing SarkomaRecruitingPhase 1Prof. Dr. Dr. Birgit BurkhardtNCT06839703Written as Dinutuximab betaHow we know
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruitingPhase 3National Cancer Institute (NCI)NCT06172296Written as DinutuximabHow we know
- Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk NeuroblastomaRecruitingPhase 1Chang Gung Memorial HospitalNCT07688252Written as Dinutuximab BetaHow we know
- Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.Not yet recruitingPhase 1/2University Hospital, Strasbourg, FranceNCT07853105Written as Dinutuximab beta, Sirolimus and IrinotecanHow we know
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabNot yet recruitingPhase 2New Approaches to Neuroblastoma Therapy ConsortiumNCT07261241Written as DinutuximabHow we know
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialRecruitingPhase 2New Approaches to Neuroblastoma Therapy ConsortiumNCT06450041Written as DinutuximabHow we know
- Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaRecruitingPhase 3Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT07375563Written as irinotecan, temozolomide, dinutuximab beta, NK-cell productHow we know
- A Multi-Arm, Platform Trial For Relapsed NeuroblastomaRecruitingPhase 1/2University of BirminghamNCT07334301Written as Dinutuximab betaHow we know
- Quadruple Immunotherapy for NeuroblastomaRecruitingPhase 2Hong Kong Children's HospitalNCT05754684Written as Dinutuximab betaHow we know
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT04221035Written as Dinutuximab BetaHow we know
- Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasRecruitingPhase 3N.N. Petrov National Medical Research Center of OncologyNCT06669013Written as dinutuximab betaHow we know
- High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)RecruitingPhase 3St. Anna KinderkrebsforschungNCT01704716Written as ch14.18/CHOHow we know
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent NeuroblastomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01711554Written as DinutuximabHow we know
- Rapid Administration Pilot for Infusing DinutuximabActive, not recruitingPhase 2Children's Hospital Los AngelesNCT05421897Written as Dinutuximab with ChemotherapyHow we know
- NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabActive, not recruitingPhase 1/2Nationwide Children's HospitalNCT04211675Written as DinutuximabHow we know
- Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed OsteosarcomaTerminatedPhase 1National Cancer Institute (NCI)NCT04751383Written as DinutuximabHow we know
- Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedPhase 3National Cancer Institute (NCI)NCT01041638Written as DinutuximabHow we know
- Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedPhase 2National Cancer Institute (NCI)NCT03786783Written as DinutuximabHow we know
- Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in ChildrenCompletedPhase 2University of BirminghamNCT02308527Written as Dinutuximab BetaHow we know
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsActive, not recruitingPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT02573896Written as DinutuximabHow we know
See all 35 studies that test dinutuximab →
Given beside what is tested · 8 — dinutuximab is usual care or a partner of the new treatment
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecruitingPhase 1/2National Cancer Institute (NCI)NCT07437963Written as DinutuximabHow we know
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingPhase 3Children's Oncology GroupNCT03126916Written as DinutuximabHow we know
- Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in NeuroblastomaRecruitingPhase 1Princess Maxima Center for Pediatric OncologyNCT06485947Written as Dinutuximab betaHow we know
- Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory NeuroblastomaActive, not recruitingPhase 1University Hospital Southampton NHS Foundation TrustNCT02914405Written as Ch14.18/CHOHow we know
- A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including NeuroblastomaCompletedPhase 1/2Eli Lilly and CompanyNCT04238819Written as DinutuximabHow we know
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaActive, not recruitingPhase 2Children's Oncology GroupNCT03794349Written as DinutuximabHow we know
- NB2013-HR German (GPOH) / Dutch (DCOG) TrialTerminatedPhase 2University of CologneNCT02641782Written as antibody ch14.18How we know
- Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)Status unknownPhase 1/2St. Anna KinderkrebsforschungNCT01701479Written as ch14.18/CHOHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing SarkomaOct 29, 2026NCT06839703
Codes
What other systems call dinutuximab · ClinicalTrials.gg INT004079
- MeSH (NLM) C112746dinutuximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7SQY4ZUD30DINUTUXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 1606274Confirmed FDA, Wikidata
- Wikidata Q21011236dinutuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1570DinutuximabOne source FDA
- DrugBank DB09077One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C112746 | dinutuximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7SQY4ZUD30 | DINUTUXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1606274 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011236 | dinutuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1570 | Dinutuximab | One source FDA |
| DrugBank | DB09077 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.